# A Study of EP0031 in Patients With Advanced RET-altered Malignancies

> **NCT05443126** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ellipses Pharma** · enrollment: 265 (estimated)

## Conditions studied

- Advanced Solid Tumor
- NSCLC

## Interventions

- **DRUG:** EP0031

## Key facts

- **NCT ID:** NCT05443126
- **Lead sponsor:** Ellipses Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-30
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443126, "A Study of EP0031 in Patients With Advanced RET-altered Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05443126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*